Issues in the Ttreatment of neurological conditions caused by reactivation of varicella zoster virus (VZV)

Kennedy, P. G.E. (2016) Issues in the Ttreatment of neurological conditions caused by reactivation of varicella zoster virus (VZV). Neurotherapeutics, 13(3), pp. 509-513. (doi: 10.1007/s13311-016-0430-x) (PMID:27032406)

Abstract

Varicella zoster virus (VZV) is a ubiquitous neurotropic human herpesvirus. Primary infection usually causes varicella (chicken pox), after which virus becomes latent in ganglia along the entire neuraxis. Decades later, virus reactivates to produce herpes zoster (shingles), a painful dermatomally distributed vesicular eruption. Zoster may be further complicated by postherpetic neuralgia, VZV vasculopathy, myelitis, and segmental motor weakness. VZV reactivation has also been associated with giant cell arteritis. This overview discusses treatment of various conditions that often require both corticosteroids and antiviral drugs. Treatment for VZV-associated disease is often based on case reports and small studies rather than large-scale clinical trials. Issues that require resolution include the optimal duration of such combined therapy, more effective treatment for postherpetic neuralgia, whether some treatments should be given orally or intravenously, the widening spectrum of zoster sine herpete, and the role of antiviral therapy in giant cell arteritis.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Kennedy, Professor Peter
• Authors: Kennedy, P. G.E.
• College/School: College of Medical Veterinary and Life Sciences > School of Infection & Immunity
• Journal Name: Neurotherapeutics
• Publisher: Springer US
• ISSN: 1933-7213
• ISSN (Online): 1878-7479
• Published Online: 31 March 2016